Transitional cell carcinoma is the most common type of bladder cancer occurring in over 90% of dogs with a confirmed bladder mass. Scottish Terriers, Westies, Beagles, Australian Shephards, and Wheatens are common breeds affected with this disease. A bladder or urethral mass is often confirmed on abdominal ultrasound. Cystoscopy and biopsy or traumatic catheterization are the standard diagnostics to determine a diagnosis. Surgery to remove the bladder mass in dogs with transitional cell carcinoma has not shown to lengthen survival times and there is also the concern for seeding the tumor to the abdominal wall or other areas with surgery/cystotomy. Vinblastine has been used to treat bladder cancer in humans; and previous studies have shown encouraging results at Purdue VTH. Based on research at PUVTH, approximately 35-40% of dogs will experience substantial shrinkage (50% or greater) of the tumor and 40-50% of dogs achieve stabilization of their cancer. Mitoxantrone and Carboplatin are chemotherapeutics, which also have shown efficacy against transitional cell carcinoma. Piroxicam is a cyclooxygenase inhibitor that has specifically been shown to be effective for the treatment of TCC; approximately 60% of dogs will have stabilization of their tumors for 4-6 months. Urethral stent placement is the most natural way to avoid urinary tract obstruction with cancers of the urinary tract and ureteral stents are used to relieve obstructions of the tubes leading from the kidneys to the urinary bladder. Contrast imaging is often used to determine if the patient is an appropriate candidacy for this procedure and for stent placement.
Join Our Family
Randhurst Animal Hospital
212 East Rand Rd., Mt. Prospect, IL 60056
Veterinarians serving Mt Prospect, Des Plaines, Arlington Heights, Northbrook, Glenview, Morton Grove, Rolling Meadows, Wheeling, Prospect Heights, Palatine and surrounding areas
Veterinary Website Design by Cheshire Partners